Sino Biopharm Advances Kylo-11 With First U.S. Patient in Phase II Trial

Sino Biopharmaceutical ( (HK:1177) ) has provided an update.

Sino Biopharmaceutical announced that its subsidiary Hangzhou Hygieia Biomedical has enrolled the first U.S. patient in a Phase II clinical trial of Kylo-11, an siRNA drug targeting the LPA gene for patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a). The study, conducted in both China and the United States, will test dosing regimens of once every six months or once a year, positioning the therapy as a potential best-in-class, ultra-long-acting treatment for a major, currently unaddressed cardiovascular risk factor.

Kylo-11 uses a dual-conjugated siRNA delivery platform that has received global patent authorization and aims to deliver durable reductions in Lp(a) levels with favorable safety and tolerability. Early Phase I data showed robust and sustained lowering of Lp(a) across multiple dose cohorts with mostly mild, unrelated adverse events, underscoring the drug’s potential to fill a global therapeutic gap and strengthen Sino Biopharmaceutical’s presence in innovative cardiovascular therapies.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a China-based pharmaceutical group engaged in the research, development, manufacturing, and commercialization of innovative medicines. Through its wholly owned subsidiary Hangzhou Hygieia Biomedical, the company focuses on cutting-edge RNA interference therapies, targeting major unmet needs in cardiovascular and other chronic diseases in global markets.

Average Trading Volume: 70,575,576

Technical Sentiment Signal: Buy

Current Market Cap: HK$108B

For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.